Incyte pens $885M biobucks AI pact to use Genesis' GEMS to develop new drugs
Incyte is sticking to its strategy this year of finding “early-stage, exotic stuff”—paying Genesis Therapeutics $30 million upfront to use the biotech’s artificial intelligence platform to develop small-molecule medicines against undisclosed targets
Incyte is sticking to its strategy this year of finding “early-stage, exotic stuff”—paying Genesis Therapeutics $30 million upfront to use the biotech’s artificial intelligence platform to develop small-molecule medicines against undisclosed targets
